Q (sonnet-5.5): is there a relationship between cic mutation and 19q del in lgg?

▶ read_guide
{
 "uri": "cbioportal://statistical-tests-guide"
}

▶ list_studies
{
 "search": "lgg"
}

▶ list_studies
{
 "search": "glioma"
}

◀ result
Statistical Test Selection Guide
================================

Purpose
-------
This guide ensures the correct statistical test is selected before performing any group comparison, matching cBioPortal's own Group Comparison defaults.

HARD RULES — NEVER FABRICATE A STATISTIC
----------------------------------------
ClickHouse cannot run statistical tests. The agent therefore must NEVER produce a derived statistic that is not a literal column value from a SQL result. Specifically:

1. **Never invent a p-value.** Not "p < 0.001", not "p ≈ 0.05", not any p-value. If the user asks "what is the p-value?", the answer is *"I can't compute that — here is the 2x2 contingency table (or group statistics). Run it in cBioPortal's Group Comparison tab, in R with `fisher.test(...)` / `wilcox.test(...)`, or in Python with `scipy.stats.fisher_exact(...)` / `mannwhitneyu(...)`."*
2. **Never claim mutual exclusivity (or co-occurrence) from a contingency table alone.** A 2x2 table is not a test. The shape "altered/not altered × group A/group B" needs Fisher's exact + a defined direction (odds ratio < 1 with significant p). Without that test, the agent presents the table and stops. Descriptive phrasing is also a claim: "largely/mostly mutually exclusive", "rarely co-occur", "tend to co-occur" are forbidden without the test — point to cBioPortal's Mutual Exclusivity tab instead.
3. **Never report a "median" that came from `AVG(...)` or any non-median aggregate.** "Median" and "mean" are different statistics; for skewed clinical distributions (especially survival) they differ substantially. Use ClickHouse's `quantile(0.5)(...)` for actual median, and label arithmetic averages as "mean", never "median".
4. **Never report a hazard ratio, odds ratio, risk ratio, or relative risk** that wasn't computed by an external tool. These require regression / model fitting that ClickHouse does not do.
5. **Never report median overall survival from `AVG(OS_MONTHS)` or even `quantile(0.5)(OS_MONTHS)`.** Median OS requires Kaplan-Meier estimation, which handles censoring (`OS_STATUS = 0:LIVING` means the event hasn't happened yet). Naive medians/means over `OS_MONTHS` ignore censoring and are systematically wrong. The correct handoff: return the raw `(OS_MONTHS, OS_STATUS)` pairs (or descriptive counts: N events, N censored, follow-up range) and tell the user to run KM in R (`survival::survfit`) or Python (`lifelines.KaplanMeierFitter`), or use cBioPortal's Survival comparison.

If asked to do any of (1)–(5), respond with the appropriate handoff template from the "Approved Response Templates" section below — do not produce the number.

Ambiguous-Term Clarification (before any analysis)
--------------------------------------------------
If the user's question uses an ambiguous term, ask before computing anything. Examples:

- **"aggressive"** → could mean shorter overall survival, higher metastasis rate, higher grade/stage, higher TMB, or specific molecular features. Ask which definit … (9984 more chars)

◀ result
{"result":[{"cancer_study_identifier":"lgggbm_tcga_pub","name":"Merged Cohort of LGG and GBM (TCGA, Cell 2016)","type_of_cancer_id":"difg","sample_count":1122,"has_guide":false,"url":"https://www.cbioportal.org/study/summary?id=lgggbm_tcga_pub"},{"cancer_study_identifier":"lgg_tcga","name":"Brain Lower Grade Glioma (TCGA, Firehose Legacy)","type_of_cancer_id":"difg","sample_count":530,"has_guide":false,"url":"https://www.cbioportal.org/study/summary?id=lgg_tcga"},{"cancer_study_identifier":"lgg_tcga_pan_can_atlas_2018","name":"Brain Lower Grade Glioma (TCGA, PanCancer Atlas)","type_of_cancer_id":"difg","sample_count":514,"has_guide":false,"url":"https://www.cbioportal.org/study/summary?id=lgg_tcga_pan_can_atlas_2018"},{"cancer_study_identifier":"lgg_ucsf_2014","name":"Low-Grade Gliomas (UCSF, Science 2014)","type_of_cancer_id":"difg","sample_count":61,"has_guide":false,"url":"https://www.cbioportal.org/study/summary?id=lgg_ucsf_2014"},{"cancer_study_identifier":"lgg_ctf_synodos_2025","name":"Pediatric Low-Grade Glioma (CTF, Acta Neuropathol 2021)","type_of_cancer_id":"difg","sample_count":31,"has_guide":false,"url":"https://www.cbioportal.org/study/summary?id=lgg_ctf_synodos_2025"}]}

◀ result
{"result":[{"cancer_study_identifier":"glioma_mskcc_2019","name":"Glioma (MSK, Clin Cancer Res 2019)","type_of_cancer_id":"difg","sample_count":1004,"has_guide":false,"url":"https://www.cbioportal.org/study/summary?id=glioma_mskcc_2019"},{"cancer_study_identifier":"difg_glass","name":"Diffuse Glioma (GLASS Consortium)","type_of_cancer_id":"difg","sample_count":693,"has_guide":false,"url":"https://www.cbioportal.org/study/summary?id=difg_glass"},{"cancer_study_identifier":"difg_tcga_gdc","name":"Diffuse Glioma (TCGA GDC, 2025)","type_of_cancer_id":"difg","sample_count":530,"has_guide":false,"url":"https://www.cbioportal.org/study/summary?id=difg_tcga_gdc"},{"cancer_study_identifier":"lgg_tcga","name":"Brain Lower Grade Glioma (TCGA, Firehose Legacy)","type_of_cancer_id":"difg","sample_count":530,"has_guide":false,"url":"https://www.cbioportal.org/study/summary?id=lgg_tcga"},{"cancer_study_identifier":"lgg_tcga_pan_can_atlas_2018","name":"Brain Lower Grade Glioma (TCGA, PanCancer Atlas)","type_of_cancer_id":"difg","sample_count":514,"has_guide":false,"url":"https://www.cbioportal.org/study/summary?id=lgg_tcga_pan_can_atlas_2018"},{"cancer_study_identifier":"difg_glass_2019","name":"Diffuse Glioma (GLASS Consortium, Nature 2019)","type_of_cancer_id":"difg","sample_count":444,"has_guide":false,"url":"https://www.cbioportal.org/study/summary?id=difg_glass_2019"},{"cancer_study_identifier":"brain_cptac_2020","name":"Pediatric Brain Cancer (CPTAC/CHOP, Cell 2020)","type_of_cancer_id":"brain","sample_count":218,"has_guide":false,"url":"https://www.cbioportal.org/study/summary?id=brain_cptac_2020"},{"cancer_study_identifier":"pcpg_tcga","name":"Pheochromocytoma and Paraganglioma (TCGA, Firehose Legacy)","type_of_cancer_id":"mnet","sample_count":184,"has_guide":false,"url":"https://www.cbioportal.org/study/summary?id=pcpg_tcga"},{"cancer_study_identifier":"pcpg_tcga_pan_can_atlas_2018","name":"Pheochromocytoma and Paraganglioma (TCGA, PanCancer Atlas)","type_of_cancer_id":"soft_tissue","sample_count":178,"has_guide":false,"url":"https://www.cbioportal.org/study/summary?id=pcpg_tcga_pan_can_atlas_2018"},{"cancer_study_identifier":"pcpg_tcga_pub","name":"Pheochromocytoma and Paraganglioma (TCGA, Cell 2017)","type_of_cancer_id":"soft_tissue","sample_count":178,"has_guide":false,"url":"https://www.cbioportal.org/study/summary?id=pcpg_tcga_pub"},{"cancer_study_identifier":"hnsc_a5consortium_2025","name":"Hereditary SDHB-Mutant Pheochromocytomas and Paragangliomas (A5 Consortium, Nature Comm 2025)","type_of_cancer_id":"hnsc","sample_count":94,"has_guide":false,"url":"https://www.cbioportal.org/study/summary?id=hnsc_a5consortium_2025"},{"cancer_study_identifier":"glioma_msk_2018","name":"Glioma (MSK, Nature 2019)","type_of_cancer_id":"difg","sample_count":91,"has_guide":false,"url":"https://www.cbioportal.org/study/summary?id=glioma_msk_2018"},{"cancer_study_identifier":"difg_msk_2023","name":"IDH-mutated Diffuse Glioma (MSK, Clin Cancer Res 2024)","type_of_cance … (855 more chars)

═ answer (success)
Several LGG studies in cBioPortal could answer this, and the choice changes the numbers. Which one do you want?

- **Brain Lower Grade Glioma (TCGA, PanCancer Atlas)** (`lgg_tcga_pan_can_atlas_2018`, 514 samples)
- **Brain Lower Grade Glioma (TCGA, Firehose Legacy)** (`lgg_tcga`, 530 samples)
- **Merged Cohort of LGG and GBM (TCGA, Cell 2016)** (`lgggbm_tcga_pub`, 1,122 samples). This one includes GBM, so it isn't LGG-only.
- **Low-Grade Gliomas (UCSF, Science 2014)** (`lgg_ucsf_2014`, 61 samples)
- **Pediatric Low-Grade Glioma (CTF)** (`lgg_ctf_synodos_2025`, 31 samples)
- **All of them**, reported separately

I'd suggest the TCGA PanCancer Atlas study. It's the largest LGG-specific cohort and should have both mutation and copy-number data.

Two things about how I'd run it:
- **Defining "19q del":** cBioPortal's standard copy-number calls are per gene, not per chromosome arm. I would either use the arm-level copy-number calls if the study has them, or use a proxy such as loss of 19q genes. I'll state which one I use.
- **What I can report:** a 2×2 table of CIC mutated vs. wild-type against 19q deleted vs. not, with profiled-sample denominators. I can't compute a p-value or odds ratio myself. I'll link the Group Comparison and Mutual Exclusivity views in cBioPortal, which run Fisher's exact test.